- Late-breaking oral presentation features echocardiographic data analysis showing favorable impact of AVIM therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failure
- Hypertension is the leading cause of diastolic dysfunction; both conditions are common in older patients and contribute to the development of heart failure
NEW HOPE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced a late-breaking oral presentation of data on the benefits of atrioventricular interval modulation (“AVIM”) therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics (“THT”) 2025 Conference in Boston, Massachusetts. The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (“Echo”) markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients.
The presentation titled "Effects of Atrioventricular Interval Modulation (AVIM) Therapy in Subjects with Hypertension and Diastolic Dysfunction" is being delivered in a late-breaking clinical science session at THT by Marat Fudim, M.D., M.H.S. Advanced Heart Failure Cardiologist, Duke Health on Wednesday, February 12, 2025, at 10:43am ET.
Dr. Fudim commented, “For many patients with long-standing hypertension, the heart can undergo structural and functional changes that result in diastolic dysfunction, the progression of which is directly linked to the development of heart failure. By reducing systolic blood pressure and favorably impacting intra-cardiac pressures and volumes, AVIM therapy directly affects diastolic filling and myocardial relaxation. This analysis of MODERATO II data provides exciting insights that suggest that, beyond lowering systolic blood pressure, AVIM therapy improves diastolic function and leads to favorable ventricular remodeling. Given the strong link between uncontrolled hypertension, diastolic dysfunction, and heart failure, these findings highlight the opportunity to intervene earlier and leverage AVIM therapy for the prevention of heart failure.”
Key Findings:
A retrospective, treatment-blinded analysis of MODERATO II assessed the impact of 6 months of AVIM therapy on systolic blood pressure (“SBP”) and Echo markers of diastolic dysfunction (“DD”) using core lab Echos with independent blinded adjudication. Patients were classified as with DD (“DD+”) or without DD (“DD-”) using the American Society of Echocardiography Guidelines. From the MODERATO II study cohort (n=47), 36 patients had technically sufficient Echo data, and 61% of this group (22/36) had Echo evidence of DD.
Using key measures of diastolic function, AVIM therapy:
- Significantly reduced office and ambulatory SBP in patients with DD through 6 months
- Ambulatory SBP (“aSBP”) was reduced in AVIM-treated DD+ patients (N=12) by 8.3±9.7 mmHg (p